Biologica Technologies showcasing Allofill™ at the annual American Society of Plastic Surgeons meeting

CARLSBAD, Calif., Oct. 16, 2015 /PRNewswire/ -- Biologica Technologies announced today that it will be exhibiting Allofill at the American Society of Plastic Surgeons (ASPS) Annual Meeting being held this week at Boston Convention and Exhibition Center, Boston, MA.  Biologica Technologies will be located in booth number 436.

Allofill is the first product of its kind; a ready to use, 'off the shelf', adipose derived injectable filler.  Allofill works with the body to provide an all-natural tissue scaffold with native growth factors, such as VEGF, aFGF and bFGF, which are important in angiogenesis and adipogenesis. Allofill retains the native extracellular matrix (ECM) components of adipose tissue and over time it will be remodeled into native soft tissue.

"At various times, autologous fat transfer or using other fillers may not be the most ideal procedure for a patient," stated President, Amit Govil.  "Allofill provides a very unique and new option for surgeons with a product that will remodel into native, host tissue and one that has more reliable results and cost savings over autologous fat transfer."

About Allofill and Biologica Technologies

Allofill can be used to fill soft-tissue defects as a non-invasive alternative to autologous fat grafting to provide cushioning and support for subcutaneous tissue. Allofill is intended for use in situations where autologous fat grafting is appropriate and should be restricted to homologous use of adipose tissue.  Allofill is currently undergoing clinical trials and will be available for sale in the near future.

Founded in 2015, Biologica Technologies is a company established to provide a variety of innovative biologic products across multiple medical specialties. Biologica's proprietary technology captures naturally occurring growth factors found within allograft tissue, providing patients and surgeons with novel biologic solutions. The company's first orthopaedic product, ProteiOS™, is a 'first of its kind' growth factor derived from minimally manipulated allogeneic bone marrow.  The company is privately-held and headquartered in Carlsbad, CA.

RELATED LINKS
http://www.biologicatechnologies.com/

SOURCE Biologica Technologies

Related Links

http://www.biologicatechnologies.com